Close Menu

NEW YORK (GenomeWeb) – Illumina and Loxo Oncology said today that they plan to develop sequencing-based pan-cancer companion diagnostics for two of Loxo's targeted oncology drugs.

The companies will use a version of Illumina's TruSight 170 panel, a hybrid capture panel launched in the beginning of 2017 that analyzes both DNA and RNA. The test will be run on Illumina's NextSeq 550Dx platform.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.